Pricing Log in Create free account

Braveheart Bio, Inc. (BRVE) vs Mineralys Therapeutics, Inc. (MLYS)

Braveheart Bio, Inc. and Mineralys Therapeutics, Inc. are both Biotechnology companies. Braveheart Bio, Inc. and Mineralys Therapeutics, Inc. are of similar size ($1.9B and $1.9B). Across the 6 metrics below, Braveheart Bio, Inc. leads on 4 and Mineralys Therapeutics, Inc. on 2.

Valuation

Metric BRVE MLYS Biotechnology median
P/E — n/m 8.58
P/S n/m n/m 10.29
P/B n/m 3.28 2.29
Price to free cash flow n/m n/m 21.93
EV/EBITDA n/m n/m 0.67
EV/Sales n/m n/m 9.89
Earnings yield — (19.86%) (31.56%)
Free cash flow yield (14.01%) (7.68%) (23.42%)

Profitability

Metric BRVE MLYS Biotechnology median
Gross margin — — 65.77%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (80.88%) (54.09%)
Return on assets 0.00% (69.67%) (47.78%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BRVE MLYS Biotechnology median
Revenue growth (TTM) — — 5.83%
EPS growth (last fiscal year) — 37.43% 29.36%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BRVE MLYS Biotechnology median
Debt to equity 0.00 0.18 0.00
Current ratio 13.63 34.46 4.80
Net debt to EBITDA 1.34 3.85 0.97

Dividend

Metric BRVE MLYS Biotechnology median
Dividend yield — — 0.44%
Payout ratio — — —

Size

Metric BRVE MLYS Biotechnology median
Market cap 1.89b 1.87b 153.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack